Fredun Pharmaceuticals Limited (BOM:539730)

Fredun Pharmaceuticals Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Assets

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash & Equivalents	649.27	6.37	10.72	29.47	19.38
Short-Term Investments	-	45.36	2.41	1.51	1.08
Trading Asset Securities	-	-	8.08	3.08	0.58
Cash & Short-Term Investments	649.27	51.73	21.21	34.05	21.04
Cash Growth	1155.15%	143.94%	-37.73%	61.84%	81.16%
Accounts Receivable	926.85	1,771	648.49	345.6	902.73
Other Receivables	-	-	-	-	0.16
Receivables	935.56	1,776	650.95	347.11	903.79
Inventory	2,698	2,399	1,750	1,501	464.6
Restricted Cash	0.54	0.5	0.38	3.38	0.26
Other Current Assets	698.31	45.02	149.49	276.34	136.81
Total Current Assets	4,982	4,272	2,572	2,162	1,526
Property, Plant & Equipment	1,176	524.89	461.53	386.26	322.82
Long-Term Investments	132.18	19.93	4.66	0.03	0.03
Other Intangible Assets	6.32	4.27	4.2	3.08	0.56
Other Long-Term Assets	124.32	52.98	33.61	21.32	19.98
Total Assets	6,421	4,874	3,076	2,573	1,870

Liabilities

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Accounts Payable	875.83	1,448	629.47	593.43	486.17
Accrued Expenses	61.01	60.62	27.98	27.47	24.45
Short-Term Debt	-	1,506	867.6	677.09	186.19
Current Portion of Long-Term Debt	1,661	69.21	59.52	33.98	-
Current Portion of Leases	197.51	12.37	-	-	-
Current Income Taxes Payable	95.41	71.16	55.35	42.9	27.91
Other Current Liabilities	77.95	113.92	28.36	21.7	12.79
Total Current Liabilities	2,969	3,281	1,668	1,397	737.5
Long-Term Debt	563.1	96.13	127.98	154.4	420.39
Pension & Post-Retirement Benefits	19.43	18.56	11.62	9.97	10.03
Long-Term Deferred Tax Liabilities	65.48	44.84	41.37	38.43	14.31
Other Long-Term Liabilities	23.13	19.77	12.04	9.67	7.05
Total Liabilities	3,640	3,460	1,861	1,609	1,189

Shareholders' Equity

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Common Stock	54.73	47.22	46.99	45.32	44.33
Additional Paid-In Capital	1,624	727.73	714.27	549.69	454.12
Retained Earnings	952.95	628.39	437.73	285.48	180.04
Comprehensive Income & Other	149.54	10.5	15.72	83.27	2.13
Total Common Equity	2,781	1,414	1,215	963.76	680.61
Minority Interest	-0	-	-	-	-
Shareholders' Equity	2,781	1,414	1,215	963.76	680.61
Total Liabilities & Equity	6,421	4,874	3,076	2,573	1,870

Additional Metrics

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Total Debt	2,422	1,684	1,055	865.47	606.59
Net Cash (Debt)	-1,772	-1,632	-1,034	-831.41	-585.54
Net Cash Growth	-	-	-	-	-
Net Cash Per Share	-110.88	-117.20	-74.24	-61.89	-47.01
Filing Date Shares Outstanding	16.42	14.16	14.1	13.6	13.3
Total Common Shares Outstanding	16.42	14.16	14.1	13.6	13.3
Working Capital	2,013	991.06	903.72	765.54	788.99
Book Value Per Share	169.39	99.81	86.17	70.88	51.18
Tangible Book Value	2,775	1,410	1,211	960.68	680.05
Tangible Book Value Per Share	169.01	99.51	85.87	70.65	51.14
Land	90.63	5.24	5.24	5.24	5.24
Buildings	341.56	220.93	220.93	210.02	210.02
Machinery	1,029	501.84	391.07	289.59	198.63

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 27, 2026

Data Sources Report a data error